πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

1,257 results for β€œFirst” Clear

  1. Amitriptyline Hydrochloride 25Mg Tablet（Hunan DongtingοΌ‰

    The First People's Hospital of Lianyungang

    Depressive Disorder

    phase 1 small molecule completed

    1 trial

  2. An adaptive, randomized, double-blind, single-center, placebo-controlled first-in-human study evaluating safety, tolerability and exposure of single and multiple ascending doses of Lactobacillus expressing CXCL12 administered topically to experimentally induced skin wounds

    Lacuna Pharma Pty Ltd

    Wound healing

    phase 1 other active

    1 trial

  3. Anlotinib hydrochloride,Penpulimab

    The First People's Hospital of Lianyungang

    Colorectal Cancer

    phase 1 small molecule active

    1 trial

  4. Anti-BCMA CAR-T cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 1 mab active

    1 trial

  5. Anti-CD19-CAR

    The First People's Hospital of Lianyungang

    Leukemia

    phase 1 mab active

    1 trial

  6. Anti-CD20 monoclonal antibody and the BTK inhibitor

    The First People's Hospital of Lianyungang

    Anti-CD20 Monoclonal Antibody

    phase 1 small molecule active

    1 trial

  7. BAO-G

    The First People's Hospital of Lianyungang

    Thoracoabdominal Aortic Aneurysm

    phase 1 other active

    1 trial

  8. Biological: LV009 injection

    The First People's Hospital of Lianyungang

    CD19+ Relapse/Refractory B-ALL

    phase 1 small molecule active

    1 trial

  9. CAR-BCMA T cells

    The First People's Hospital of Lianyungang

    Refractory or Relapsed Multiple Myeloma

    phase 1 gene therapy active

    1 trial

  10. CAR-T cell infusion

    The First People's Hospital of Lianyungang

    Hematolymphoid Malignancies

    phase 1 small molecule active

    1 trial

  11. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  12. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  13. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  14. CD19 and BCMA-targeted allogeneic CAR-T cells

    The First People's Hospital of Lianyungang

    Refractory Immune-mediated Platelet Transfusion Refractoriness

    phase 1 gene therapy active

    1 trial

  15. CD19/BCMA-Targeted Universal Chimeric Antigen Receptor T Cells (UCAR-T) infusing

    The First People's Hospital of Lianyungang

    Refractory Idiopathic Membranous Nephropathy

    phase 1 small molecule active

    1 trial

  16. CLEVER PEPTIDE : Open-label, non-controlled, multicenter, dose escalation, first-in-human clinical trial to evaluate the safety, pharmacokinetics and preliminary antitumor activity of intravenous PEP-010, administered as single agent and in combination with paclitaxel or with gemcitabine in patients with recurrent and/or metastatic solid cancer

    The George Institute

    Patients with recurrent and/or metastatic solid cancer.

    phase 1 other active

    1 trial

  17. CS-101

    The First People's Hospital of Lianyungang

    Beta-Thalassemia

    phase 1 mab completed

    1 trial

  18. CT-996

    The First People's Hospital of Lianyungang

    Type 2 Diabetes

    phase 1 small molecule completed

    1 trial

  19. CTA101

    The First People's Hospital of Lianyungang

    Diffuse Large B-cell Lymphoma

    phase 1 mab active

    1 trial

  20. CVA

    The First People's Hospital of Lianyungang

    Acute Myeloid Leukemia

    phase 1 small molecule active

    1 trial

  21. Chimeric antigen receptor T cell

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  22. Chinese Herbal Compound Ointment

    The First People's Hospital of Lianyungang

    Atrophic Vaginitis

    phase 1 small molecule active

    1 trial

  23. ClinOleic (Baxter Healthcare, Deerfield, IL, USA)

    The First People's Hospital of Lianyungang

    Nutritional Supplement Toxicity

    phase 1 small molecule active

    1 trial

  24. Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion

    The First People's Hospital of Lianyungang

    Diffuse Large B Cell Lymphoma (DLBCL)

    phase 1 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources